Kimberly Manhard

Kimberly Manhard, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Heron Therapeutics, Inc. /DE/ and Inhibrx Biosciences, Inc. Over a trading history stretching from 24 April 2017 to 15 September 2026, the count stands at 59 filings.

The open-market side counts 1 purchase for €126k alongside 18 sales for €2.3M. The net balance comes to €2.2M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 10 share grants and 24 option exercises. So far in 2026, the count stands at no purchases and 5 sales.

The newest entry dates from 15 September 2026: an open-market sale of €48k, in Inhibrx Biosciences, Inc. The latest purchase dates back some time: it was published 784 days ago, on 30 August 2024. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.